A Phase 2, Multicenter, Open-label, Single-arm Study of ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2017
At a glance
- Drugs Tivantinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Kyowa Hakko Kirin
- 07 Jun 2017 Biomarkers information updated
- 17 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Mar 2015 Planned End Date changed from 1 Nov 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.